A comprehensive view of novavax inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.
Novavax's updated non-mRNA COVID-19 vaccine, Nuvaxovid XBB.1.5, now available in UK for 2024 vaccination season following receipt of wholesale license and green book update
Published:
April 18, 2024
by Novavax Inc.
|
Novavax investor Shah Capital attempting to nominate two new independent board directors; Shah claims Novavax has been historically mismanaged
Published:
April 15, 2024
by FiercePharma
|
Activist investor critical of Novavax for not using mRNA vaccination fears to boost sales of its COVID-19 vaccine; Shah Capital wants Novavax to market its protein-based vaccine directly to people concerned about safety of mRNA vaccines
Published:
April 15, 2024
by Quartz
|
Shah Capital nominates two highly qualified independent director candidates for Novavax
Published:
April 15, 2024
by GlobeNewswire
|
Australia: Novavax Receives Patent for 'Methods and compositions for inducing immune responses against clostridium difficile'
Published:
April 05, 2024
by Australian Government
|
Ask us about our Health Care Sector market view